MCID: LYM157
MIFTS: 31

Lymph Node Carcinoma

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymph Node Carcinoma

MalaCards integrated aliases for Lymph Node Carcinoma:

Name: Lymph Node Carcinoma 12 15
Lymph Node Neoplasm 12 52
Lymph Node Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0080618 DOID:10619
NCIt 49 C35497
SNOMED-CT 67 127232002
UMLS 71 C0596869

Summaries for Lymph Node Carcinoma

Disease Ontology : 12 A lymphatic system cancer that is located in the lymph node.

MalaCards based summary : Lymph Node Carcinoma, also known as lymph node neoplasm, is related to lymph node adenoid cystic carcinoma and lymphoma, hodgkin, classic. An important gene associated with Lymph Node Carcinoma is LRRC26 (Leucine Rich Repeat Containing 26). The drugs nivolumab and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder. Affiliated tissues include lymph node, prostate and t cells.

Related Diseases for Lymph Node Carcinoma

Diseases related to Lymph Node Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 lymph node adenoid cystic carcinoma 11.3
2 lymphoma, hodgkin, classic 11.3
3 kaposi sarcoma 10.5
4 epilepsy, idiopathic generalized 4 10.3 FOLH1 AR
5 epilepsy, idiopathic generalized 5 10.3 FOLH1 AR
6 prostate adenoid cystic carcinoma 10.0 KLK3 AR
7 prostate leiomyoma 9.9 KLK3 AR
8 prostate calculus 9.9 KLK3 AR
9 rhabdomyosarcoma, embryonal, 1 9.9
10 pancytopenia 9.9
11 splenic disease 9.9
12 rhabdomyosarcoma 9.9
13 fibrosarcoma of bone 9.9
14 fibrosarcoma 9.9
15 histiocytosis 9.9
16 splenomegaly 9.9
17 prostatic acinar adenocarcinoma 9.9 KLK3 AR
18 breast cancer 9.9
19 lymphoma, mucosa-associated lymphoid type 9.9
20 thyroid carcinoma, familial medullary 9.9
21 parathyroid carcinoma 9.9
22 lung cancer susceptibility 3 9.9
23 large cell neuroendocrine carcinoma 9.9
24 lymphoma 9.9
25 nodal marginal zone lymphoma 9.9
26 neuroendocrine carcinoma 9.9
27 endodermal sinus tumor 9.9
28 rectum cancer 9.9
29 adenocarcinoma 9.9
30 papillary adenocarcinoma 9.9
31 thyroid gland medullary carcinoma 9.9
32 tubular adenocarcinoma 9.9
33 testicular yolk sac tumor 9.9
34 thyroid carcinoma 9.9
35 prostate transitional cell carcinoma 9.8 KLK3 AR
36 colorectal cancer 9.8
37 reticulum cell sarcoma 9.8
38 gastric cancer 9.8
39 melanoma, cutaneous malignant 10 9.8
40 small cell carcinoma 9.8
41 goiter 9.8
42 leukemia 9.8
43 nodular goiter 9.8
44 melanoma 9.8
45 papillary carcinoma 9.8
46 thyroiditis 9.8
47 prostatic hyperplasia, benign 9.8 KLK3 AR
48 lymphocele 9.8 KLK3 FOLH1
49 bladder lateral wall cancer 9.8 KLK3 FOLH1
50 withdrawal disorder 9.8 KLK3 AR

Graphical network of the top 20 diseases related to Lymph Node Carcinoma:



Diseases related to Lymph Node Carcinoma

Symptoms & Phenotypes for Lymph Node Carcinoma

Drugs & Therapeutics for Lymph Node Carcinoma

Drugs for Lymph Node Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
nivolumab Approved Phase 1 946414-94-4
2 Antineoplastic Agents, Immunological Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 18F-Fluciclovine PET CT as an Indicator of Therapeutic Response in Metastatic Prostate Carcinoma (M1PCa) Recruiting NCT04134208 Phase 4 Fluciclovine F18
2 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Recruiting NCT01149161 Phase 2, Phase 3
3 A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology Completed NCT01667536 Phase 2 Drug: 99mTc-MIP-1404
4 Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases Completed NCT01447056 Phase 1
5 Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE) Active, not recruiting NCT02973113 Phase 1
6 Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx T1-T2N0 Operable : Comparison of the Reference Strategy Based on a the Systematic Lymph Node Dissection Versus the Strategy Based on the Technique of Sentinel Lymph Node. Completed NCT02855723
7 Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy Recruiting NCT00039676
8 Feasibility Study of High Dose Stereotactic Body Radiation Therapy (SBRT) for Lymph Nodal Lesions in Oligometastatic Patients for Genito-urinary, Gastro-intestinal and Gynaecological Cancer Active, not recruiting NCT02570399

Search NIH Clinical Center for Lymph Node Carcinoma

Genetic Tests for Lymph Node Carcinoma

Anatomical Context for Lymph Node Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Lymph Node Carcinoma:

19
Lymph Node

MalaCards organs/tissues related to Lymph Node Carcinoma:

40
Lymph Node, Prostate, T Cells, Thyroid, Breast, Brain

Publications for Lymph Node Carcinoma

Articles related to Lymph Node Carcinoma:

(show top 50) (show all 91)
# Title Authors PMID Year
1
The Effect of Arbutin on The Expression of Tumor Suppressor P53, BAX/BCL-2 Ratio and Oxidative Stress Induced by Tert-Butyl Hydroperoxide in Fibroblast and LNcap Cell Lines. 61
32347047 2021
2
Preliminary in Vitro Studies on Corynebacterium urealyticum Pathogenetic Mechanisms, a Possible Candidate for Chronic Idiopathic Prostatitis? 61
32218312 2020
3
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. 61
31541034 2020
4
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands. 61
31260881 2019
5
Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring. 61
30858765 2019
6
A Case of Mediastinal Lymph Node Carcinoma of Unknown Primary Site. 61
30488402 2018
7
Development of pipette tip gap closure migration assay (s-ARU method) for studying semi-adherent cell lines. 61
30069611 2018
8
Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma. 61
29143229 2018
9
Cervical lymph node carcinoma metastasis from unknown primary site: a retrospective analysis of 154 patients. 61
29608251 2018
10
Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. 61
29324665 2018
11
Anticancer effect of Saussurea lappa extract via dual control of apoptosis and autophagy in prostate cancer cells. 61
28746210 2017
12
Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. 61
27789722 2017
13
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity. 61
28797006 2017
14
Superporous Poly(ethylene glycol) Diacrylate Cryogel with a Defined Elastic Modulus for Prostate Cancer Cell Research. 61
27240250 2016
15
Predictable Heating and Positive MRI Contrast from a Mesoporous Silica-Coated Iron Oxide Nanoparticle. 61
26991550 2016
16
Hibiscus sabdariffa Leaf Extract Inhibits Human Prostate Cancer Cell Invasion via Down-Regulation of Akt/NF-kB/MMP-9 Pathway. 61
26115086 2015
17
Regulation of T-type calcium channel expression by sodium butyrate in prostate cancer cells. 61
25557765 2015
18
ZnFe2O4 nanoparticles as radiosensitizers in radiotherapy of human prostate cancer cells. 61
25492003 2015
19
Acridone alkaloids with cytotoxic and antimalarial activities from Zanthoxylum simullans Hance. 61
24696549 2014
20
[Metastatic thoracic lymph node carcinoma from extra-thoracic malignancy or from unknown primary site]. 61
24210159 2013
21
Relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated with TS-1 alone: a case report. 61
24370171 2013
22
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. 61
24167294 2013
23
[Mediastinal lymph node carcinoma of unknown primary site; report of a case]. 61
23917060 2013
24
CT-guided percutaneous chemoablation using an ethanol-ethiodol-doxorubicin emulsion for the treatment of metastatic lymph node carcinoma: a comparative study. 61
22905808 2013
25
Integration of the transcriptome and glycome for identification of glycan cell signatures. 61
23326219 2013
26
In vivo pH imaging with (99m)Tc-pHLIP. 61
22371188 2012
27
Effect of lithium chloride and antineoplastic drugs on survival and cell cycle of androgen-dependent prostate cancer LNCap cells. 61
23248400 2012
28
[Mediastinal lymph node carcinoma of unknown primary site; report of a case]. 61
22647337 2012
29
Multimodal treatment for multistation mediastinal lymph node adenocarcinoma: a case report. 61
22001212 2012
30
A case of mediastinal lymph node carcinoma of unknown primary site treated with docetaxel and cisplatin with concurrent thoracic radiation therapy. 61
22189482 2011
31
[Experience of long term survival in a case with surgery for cancer metastasis to brain and mediastinal lymph node from unknown primary site]. 61
21766710 2011
32
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. 61
21624609 2011
33
Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells. 61
20736324 2010
34
Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. 61
19747763 2010
35
Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. 61
20574928 2010
36
The bioactive compounds alpha-chaconine and gallic acid in potato extracts decrease survival and induce apoptosis in LNCaP and PC3 prostate cancer cells. 61
20574921 2010
37
Mediastinal lymph node carcinoma of an unknown primary site: clinicopathological examination. 61
19440819 2009
38
Anti-androgenic activity of fatty acids. 61
19353546 2009
39
Prostate-specific membrane antigen and its truncated form PSM'. 61
19107881 2009
40
[Mediastinal lymph node carcinoma of unknown primary site; report of a case]. 61
19280962 2009
41
Anti-androgen effects of extracts and compounds from Ganoderma lucidum. 61
19235153 2009
42
Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. 61
19017637 2009
43
Induction of apoptosis by lupeol and mango extract in mouse prostate and LNCaP cells. 61
18444143 2008
44
Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. 61
18444160 2008
45
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. 61
17914087 2007
46
Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells. 61
17218080 2007
47
TRPM8-independent menthol-induced Ca2+ release from endoplasmic reticulum and Golgi. 61
17142461 2007
48
Metastatic thoracic lymph node carcinoma of unknown origin on which we performed two kinds of immunohistochemical examinations. 61
16977301 2006
49
BKCa channels activating at resting potential without calcium in LNCaP prostate cancer cells. 61
16604468 2005
50
Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. 61
15958518 2005

Variations for Lymph Node Carcinoma

Expression for Lymph Node Carcinoma

Search GEO for disease gene expression data for Lymph Node Carcinoma.

Pathways for Lymph Node Carcinoma

GO Terms for Lymph Node Carcinoma

Cellular components related to Lymph Node Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 TRPC1 LRRC55 LRRC52 LRRC38 LRRC26 KCNMB4
2 voltage-gated potassium channel complex GO:0008076 9.1 LRRC55 LRRC52 LRRC38 LRRC26 KCNMB4 KCNMA1

Biological processes related to Lymph Node Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.7 TRPC1 LRRC55 LRRC52 LRRC38 LRRC26 KCNMB4
2 potassium ion transport GO:0006813 9.5 LRRC52 KCNMB4 KCNMA1
3 potassium ion transmembrane transport GO:0071805 9.43 LRRC55 LRRC52 LRRC38 LRRC26 KCNMB4 KCNMA1
4 regulation of systemic arterial blood pressure GO:0003073 9.26 KLK3 AR
5 positive regulation of voltage-gated potassium channel activity GO:1903818 8.92 LRRC55 LRRC52 LRRC38 LRRC26

Molecular functions related to Lymph Node Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel binding GO:0044325 9.55 TCAF1 LRRC55 LRRC52 LRRC38 LRRC26
2 voltage-gated potassium channel activity GO:0005249 9.35 LRRC55 LRRC52 LRRC38 LRRC26 KCNMA1
3 calcium-activated potassium channel activity GO:0015269 9.26 KCNMB4 KCNMA1
4 potassium channel activator activity GO:0099104 8.92 LRRC55 LRRC52 LRRC38 LRRC26

Sources for Lymph Node Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....